<DOC>
	<DOCNO>NCT00430963</DOCNO>
	<brief_summary>IncobotulinumtoxinA ( Xeomin ) botulinum toxin type A preparation free complexing protein , i.e . free protein active toxin . Injected muscle , IncobotulinumtoxinA ( Xeomin ) cause local weakening . Botulinum toxin type A widely use aesthetic treatment facial line . This study investigate efficacy safety IncobotulinumtoxinA ( Xeomin ) treatment glabellar frown line compare placebo . The study consist Main Period Open-Label Extension [ OLEX ] Period 120 day .</brief_summary>
	<brief_title>IncobotulinumtoxinA ( Xeomin ) Versus Placebo Treatment Glabellar Frown Lines</brief_title>
	<detailed_description />
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>â€¢Moderate severe glabellar frown line Previous insertion permanent material glabellar area Neuromuscular function disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>